Tracks bone thinning from steroid treatment in people with rheumatic diseases or psoriasis
Builds a databank of bone health in adults taking steroids for inflammatory conditions.
Plain-language title generated from the registry record
Registry title: Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
Key facts
- Where
- Berlin, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a long-lasting inflammatory rheumatic disease or psoriasis who take, or will soon start, glucocorticoid treatment. A control group without these diseases is also included.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Chronic inflammatory rheumatic disease or psoriasis (the control group has neither).
- Earlier treatment
- Patients have had glucocorticoid treatment already, or a new long-term glucocorticoid treatment is expected. The control group does not need this.
Main reasons for not taking part
- Alcohol, medication or drug addiction
- Severe mental illness that limits understanding of the study
- Pregnant or breastfeeding patients
- Cannot give informed consent for any reason
- Prisoners and people held in an institution by official or court order
Read by machine on 9 November 2026.
Where in Germany
- Charité University Medicine Berlin (CCM)Berlin, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prof Dr Frank Buttgereit
- Trial code
- NCT02719314
- Record updated
- 29 October 2026
- Original description
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis). The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.Read full original descriptionShow less
Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis). The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.
Inclusion: Every patient has to fulfill the following inclusion criteria:; patients with (control group: without) a diagnosis of a chronic inflammatory rheumatic disease or psoriasis; patients who (not for control groups) have/had already a glucocorticoid therapy, or patients in which the implementation of a new long-term GC therapy is expected; patients who, according to the Dachverband Osteologie (DVO, Germany) guidelines, attend our osteoporosis and bone metabolism outpatient consultation hours or are referred by the hospital wards of the Charité for diagnosis, treatment or follow-up; capability to understand the patient information; consent to participation in the project and storage of data.
Exclusion: alcohol, medication and/or drug addiction; severe psychiatric diseases limiting the comprehension of the project plan and the study protocol (persons incapable of giving informed consent); If any of the following exclusion criteria is true, the patient must not be included in this study:; pregnant and lactating patients; patients incapable of giving informed consent for any reason; prisoners and all persons who are committed to an institution due to an official or judicial order.